There are few sectors as hot right now as marijuana stocks -- click here to read our in-depth series on the industry. But even among these, GW Pharmaceuticals (GWPH) stands above the rest.
On Monday, its stock traded for $45 per share. By Tuesday, it had shot up to $61 after Morgan Stanley upgraded it to "overweight" and gave it a $103 price target. The investment bank's thesis is that a cannabis-based drug GW Pharmaceuticals is developing could soon get approval to treat pediatric epilepsy -- to learn more about this, click here. And if that happens, in turn, Morgan Stanley predicts that the company could generate $1.35 billion in sales.
Suffice it to say, the news had the financial world atwitter. Among others, it prompted CNBC's Jim Cramer to proclaim that, "When people ask me, Jim, what marijuana stock do you like? [...] I always go with GW Pharmaceuticals. This is a real company."
But does this mean the average investor should buy stock in this high flying cannabis-focused biopharmaceutical company? In the video below, Motley Fool contributor John Maxfield shares his take.
